Press release
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature cardiovascular diseases. About 1 in 250 people around the world have HeFH and only about 10% of people with this medical condition have been diagnosed. Diagnosis is important because there are several early aggressive treatments available which can lower the risk for heart diseases or stroke.
Get the detailed analysis @ https://www.pharmaproff.com/report/hefh-therapeutics-pipeline-analysis
The drug candidates of HeFH pipeline include, but not limited to, GEM-201 and anacetrapib. Some of the other companies having drugs in the HeFH pipeline includes Gemphire Therapeutics Inc. and Merck & Co. Inc.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1135
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis here
News-ID: 1727305 • Views: …
More Releases for HeFH
LEQVIO Sales Surge Globally, Driven by Rising Cardiovascular Risk Awareness and …
DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" delivers a comprehensive analysis of LEQVIO's commercial performance, competitive positioning, and future outlook across key global markets. Developed by Novartis, LEQVIO (inclisiran) is a first-in-class small interfering RNA (siRNA) therapy approved for the treatment of adults with hypercholesterolemia or mixed dyslipidemia, particularly in patients who require additional LDL-C lowering despite statin therapy.
The report provides detailed insights into LEQVIO's mechanism of action,…
Hypercholesterolemia Pipeline: 25+ Leading Innovators Driving the Future of Chol …
The hypercholesterolemia market is being reshaped by biologics, RNA-based therapies, and gene-editing tools developed by industry leaders such as Amgen, Novartis, Verve Therapeutics, Arrowhead Pharmaceuticals, and LIB Therapeutics. With innovations like PCSK9 inhibitors, ANGPTL3 silencers, and CRISPR-based precision therapies, companies are offering more durable lipid-lowering solutions beyond statins. These advancements are setting the stage for personalized cholesterol management, particularly in patients who are genetically predisposed or intolerant to statins.
DelveInsight's "Hypercholesterolemia…
Heterozygous Familial Hypercholesterolemia Drug Market Comprehensive Industry Tr …
The Heterozygous Familial Hypercholesterolemia (HeFH) Drug market is experiencing significant growth, driven by increasing awareness of cardiovascular diseases and the urgent need for effective cholesterol-lowering therapies. HeFH is a genetic condition that leads to elevated levels of low-density lipoprotein (LDL) cholesterol, raising the risk of heart disease. As healthcare systems aim to combat the rising prevalence of cardiovascular disorders, the demand for innovative treatments for HeFH is at an all-time…
Future of Heterozygous Familial Hypercholesterolemia Drug Market: Analysis and L …
𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐚𝐧𝐝 𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬
The Heterozygous Familial Hypercholesterolemia (HeFH) Drug Market is experiencing significant growth, characterized by the increasing prevalence of high cholesterol levels and the corresponding need for effective treatment solutions. HeFH is a genetic disorder that leads to elevated levels of low-density lipoprotein (LDL) cholesterol in the bloodstream, resulting in a heightened risk of cardiovascular diseases. This market is not only relevant for healthcare providers but…
Heterozygous Familial Hypercholesterolemia Drug Market Worldwide Industry Analys …
Heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period. Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial hypercholesterolemia across the…
Insights on the Heterozygous Familial Hypercholesterolemia Drug Market to 2027 | …
The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial…
